

CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax: (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 14.11.2018

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai -400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.11.2018

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Wednesday at 5:00 p.m. at the registered office of the company at Survey No. 249, Brahmanapally Village, Hayatnagar Mandal - 501511, Telangana, the Un - Audited financial results for the quarter ended 30.09.2018 along with Limited Review Report was considered and approved.

The meeting concluded at 5.30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman and whole-time Director
DIN: 01764665

Encl: as above



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th September 2018						
(Rs. in Lakhs)						
Particulars	Quarterly ended			Half Yearly Ended		Year ended
	30-Sep-18 (Unaudited)	30-Jun-18 (Unaudited)	30-Sep-17 (Unaudited)	April 2018 to Sept 2018 (Unaudited)	April 2017 to Sept 2017 (Unaudited)	31-Mar-18 (Audited)
I Revenue from Operations						
a. Net sales from Operations	1,149.10	1,303.18	376.71	2,452.28	2,474.05	5,179.72
b. Other Operating Income						-
II Other Income	1.90	2.62	-	4.52	0.98	13.58
III Total Revenue (I+II)	1,151.00	1,305.80	376.71	2,456.80	2,475.03	5,193.31
IV Expenses						
a. Cost of Material Consumed	760.96	1,184.58	163.25	1,945.54	2,367.56	4,650.17
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	164.69	91.22	41.37	73.47	388.64	320.38
c. Employees Benefit Expenses	84.46	52.72	83.79	137.18	139.39	197.42
d. Finance Costs	38.95	41.47	30.03	80.43	87.83	188.40
e. Depreciation and Amortisation expense	54.81	54.16	57.32	108.97	112.29	240.14
f. Other expenses	42.20	56.97	75.26	99.18	142.12	173.68
Total Expenses	1,146.07	1,298.68	368.28	2,444.76	2,460.55	5,129.44
Profit/ (Loss) before Exceptional item and tax (III-IV)	4.93	7.11	8.43	12.04	14.48	63.87
V Exceptional Items						
VI Profit/ (Loss) before tax (V-VI)	4.93	7.11	8.43	12.05	14.48	63.87
VII Tax Expense:	1.20	(5.66)	2.53	(4.46)	4.34	31.45
VIII a. Current tax	8.92	1.45	2.53	10.38	4.34	37.58
b. Deferred tax charge/credit	-	7.11	-	14.83	-	6.13
c. MAT Credit						
IX Profit/ (Loss) for the period (VII-VIII)	3.73	12.78	5.90	16.51	10.14	32.42
X Other Comprehensive Income						
Items that will not be reclassified to profit or loss						
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	3.73	12.78	5.90	16.51	10.14	32.42
XI Paid-up equity share capital	786.18	786.18	724.80	786.18	724.80	786.18
(Face value of the share- Rs. 10 each)						
Other Equity	1,257.58	1,192.46	-	1,257.58	-	1,146.14
XII Earnings per share (of Rs. 10 each)						
XIII a. Basic (in Rs)	0.05	0.16	0.08	0.21	0.14	0.41
b. Diluted (in Rs)	0.05	0.16	0.08	0.21	0.14	0.41

Notes:


- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) Prescribed under section 133 of the companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14 August, 2018
- The figures of the quarter ended March 31, 2018 are the balancing figures between Audited figures in respect of the full financial year upto March 31, 2018 and the unaudited published year to date figures upto December 31, 2017, which were subjected to limited review by the statutory auditors.
- The company operates in only one Segment viz., "Pharmaceutical Products"
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

Place: Hyderabad
Date: 14-11-2018

For CONCORD DRUGS LIMITED


S. Nani Reddy

Chairman



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

CONCORD DRUGS LIMITED			
Balance Sheet as at 30th September 2018			
Amount in Lakhs			
	Particulars	As at 30-09-2018	As at 31-03-2018
I	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	1,165.33	1,272.38
	(b) Investment Property	78.60	78.60
	Financial assets		
	(a) Loans & Advances	50.02	50.02
	(b) Trade receivables	2,151.38	4,982.06
	Other Non current assets	137.07	38.48
	Total Non - Current Assets	3,582.39	6,421.54
2	CURRENT ASSETS:		
	(a) Inventories	1,941.87	1,861.94
	Financial Assets		
	(a) Investments		
	(b) Trade receivables	5,019.88	2,135.17
	(c) Cash and cash equivalents	8.85	4.08
	(d) Bank balances other than (c) above	2.59	1.49
	(e) Other Current Financial Assets	29.29	12.71
	Other current assets	229.17	204.47
		7,231.64	4,219.85
	TOTAL	10,814.03	10,641.39
II	EQUITY AND LIABILITIES:		
1	EQUITY:		
	(a) Equity Share Capital	786.18	786.18
	(b) Other Equity	1,257.58	1,146.14
		2,043.75	1,932.31
2	LIABILITIES:		
i	NON-CURRENT LIABILITIES:		
	Financial Liabilities		
	(a) Borrowings	303.85	340.85
	(b) Trade payables	3,739.05	3,726.15
	Deferred tax liabilities (Net)	6.40	21.23
	Provisions	214.36	214.36
	Government Grants	57.94	61.75
		4,321.60	4,364.34
ii	CURRENT LIABILITIES:		
	Financial Liabilities		
	(a) Borrowings	975.08	900.51
	(b) Trade payables	2,920.76	2,910.68
	(c) Other Current financial	4.42	121.06
	Current Tax Liabilities (Net)	47.96	37.58
	Other current liabilities	500.46	374.90
		4,448.68	4,344.73
	TOTAL	10,814.03	10,641.38
For N.G Rao and Associates Chartered Accountants FRN- 0093995			
G. Nageswara Rao Partner Mno-207300			
Place: Hyderabad Date: 14-11-2018			



**Limited review Report on Quarterly unaudited standalone financial results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To
Board of Directors of
M/s. Concord Drugs Limited.


We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Concord Drugs Ltd ("the Company") for the quarter ended 30-09-2018, and year-to-date results for the period from 01 April, 2018 to 30 September 2018 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the company in their meeting held on 14-11-2018. Our responsibility is to issue a report on these financial statements

We conducted our review in accordance with the Standard on Review Engagement ('SRE') 2410, 'Review of Interim Financial Statements performed by the Independent Auditor of the Entity' specified u/s 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e., IndAS prescribed under section 133 of the Act and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G RAO & ASSOCIATES
Chartered Accountants
FRNo.009399S




Partner: G Nageswara Rao
Membership No.207300
Place: Hyderabad
Date: 14-11-2018